Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Form 144 filing by Ionis Pharmaceuticals (IONS) reports a proposed sale of 49,800 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $3,249,734.00. The shares are listed on Nasdaq and the filing lists 159,391,229 shares outstanding for the issuer. The securities were acquired on 01/02/2019 by option exercise from the issuer and the intended sale is scheduled for 09/30/2025 with payment in cash. The filer reports no sales in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Ionis Pharmaceuticals announced positive topline results from the pivotal study of zilganersen 50 mg in children and adults with Alexander disease (AxD). The drug met the study's primary endpoint: stabilization in gait speed on the 10-Meter Walk Test at week 61, showing a mean difference of 33.3% (p=0.0412) versus control. The company reports consistent benefit across key secondary endpoints related to patient- and clinician-reported measures and says safety and tolerability were favorable, with most adverse events mild or moderate and serious adverse events numerically lower in the zilganersen arm.
Ionis plans to submit a new drug application to the U.S. FDA in Q1 2026 and is evaluating an Expanded Access Program in the U.S. Detailed data will be presented at an upcoming medical conference.
Patrick R. O'Neil, Executive Vice President, Chief Legal Officer and General Counsel of Ionis Pharmaceuticals (IONS), reported option exercise and an offsetting sale on 09/12/2025. He exercised a non-qualified stock option to purchase 1,700 shares at a $56.78 exercise price and concurrently sold 1,700 shares under a Rule 10b5-1 trading plan for a weighted average price of $64.5807, leaving him with 55,503 shares directly owned and 57,130 shares following the transactions as reported. The filing includes an explanation that the shares sold were transacted at prices ranging from $64.53 to $64.605 and that the sale was pursuant to a 10b5-1 plan adopted May 2, 2025.
Insider transactions by Joseph T. Baroldi at Ionis Pharmaceuticals (IONS) On 09/09/2025 Mr. Baroldi executed related transactions reported on Form 4. He exercised a non-qualified stock option with a $31.80 exercise price to acquire 11,950 shares and, pursuant to a Rule 10b5-1 trading plan adopted May 2, 2025, sold 11,950 shares at a weighted-average price of $62.1622 (individual sale prices ranged $62.00–$62.44). The Form 4 shows beneficial ownership figures of 43,876 shares (after the acquisition line) and 31,926 shares (after the sale line), and additionally notes 3,071 shares indirectly owned by his spouse. The filing was signed by an attorney-in-fact on 09/10/2025.
Insider transactions by Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS): The Form 4 reports multiple transactions dated 09/09/2025 showing both acquisitions and dispositions of Ionis common stock and related options. The reporting person acquired 21,000 shares (20,000 and 1,000) via option-related transactions at exercise prices shown and sold 21,000 shares under a Rule 10b5-1 trading plan at a weighted average sale price of $64.5553 per share. Following the reported activity the filer beneficially owns between 57,130 and 77,203 shares depending on the line item.
The filing discloses that the sales were made pursuant to a 10b5-1 plan adopted May 2, 2025, and that the reported sale price is a weighted average reflecting multiple executions between $64.50 and $64.66. The filer offers to provide detailed per-trade prices on request.
Joseph T. Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals (IONS), reported multiple Section 16 transactions on 09/05/2025 under a previously adopted Rule 10b5-1 plan. He exercised 250 non-qualified stock options with a $31.80 exercise price and immediately acquired 250 shares. Simultaneously, he sold 250 shares pursuant to his 10b5-1 plan at an average price of $62, leaving him with 32,176 shares directly and 3,071 shares indirectly held by his spouse. After the option exercise, total direct beneficial ownership of common stock reported is 53,650 shares.
The filing discloses the trades were executed pursuant to a 10b5-1 trading plan adopted May 2, 2025, and the Form 4 was signed by an attorney-in-fact on 09/09/2025. No other compensatory or material corporate events are disclosed in this Form 4.
Insider sale recorded on Form 4: Ionis Pharmaceuticals EVP and Chief Scientific Officer C. Frank Bennett sold 6,000 shares of Ionis common stock on 09/05/2025 at a weighted average price of $59.5968 per share, reducing his beneficial ownership to 82,679 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, and occurred in multiple transactions at prices ranging from $59.25 to $59.86. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Bennett on 09/09/2025.
Eric Swayze, EVP Research at Ionis Pharmaceuticals (IONS), reported insider sales on 09/02/2025. He sold 10,000 shares at a weighted average price of $49.22 and 1,130 shares at a weighted average price of $53.6829 under a Rule 10b5-1 trading plan adopted August 14, 2024. After these transactions the filing shows beneficial ownership figures of 38,432 and 37,302 shares respectively, and an indirect holding of 184 shares held by his son. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Joseph H. Wender, a director of Ionis Pharmaceuticals, Inc. (IONS), reported multiple sales under a Rule 10b5-1 trading plan adopted December 16, 2024. On 09/02/2025 he reported disposing of 11,200 shares at a weighted-average price of $55.0386 (sales priced between $55.000 and $55.180) and disposing of 5,600 shares at a weighted-average price of $57.5311 (prices between $57.500 and $57.575), leaving his beneficial ownership at 120,035 shares after that transaction. On 09/03/2025 he reported disposing of 11,200 shares at a weighted-average price of $60.1383 (prices between $60.00 and $60.53), leaving his beneficial ownership at 108,835 shares. The Form 4 was signed by Patrick R. O'Neil as attorney-in-fact for Mr. Wender on 09/04/2025.
Insider sale reported by Director B. Lynne Parshall of Ionis Pharmaceuticals (IONS). On 09/02/2025 the reporting person sold a total of 20,000 shares of Ionis common stock in two transactions executed under a Rule 10b5-1 trading plan adopted May 6, 2025. The first block of 10,750 shares was sold at a weighted-average price of $50.42 (individual trades ranged $50.0137–$50.92) leaving 75,594 shares beneficially owned after the sale. The second block of 9,250 shares was sold at a weighted-average price of $51.49 (individual trades ranged $51.24–$51.81) leaving 66,344 shares beneficially owned after that sale. The Form 4 was signed by an attorney-in-fact on 09/04/2025.